Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Inovio Pharmaceuticals, Inc. (INO)

Core Viewpoint - A securities class action lawsuit has been filed against Inovio Pharmaceuticals, alleging that the company misled investors regarding the manufacturing deficiencies of its CELLECTRA device and the regulatory prospects of its INO-3107 BLA [1][2]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the Eastern District of Pennsylvania on behalf of all individuals or entities who purchased Inovio securities between October 10, 2023, and December 26, 2025 [1]. - The complaint claims that Inovio failed to disclose significant issues, including deficiencies in manufacturing for the CELLECTRA device and the unlikelihood of submitting the INO-3107 BLA to the FDA by the second half of 2024 [2]. Group 2: Allegations Against Inovio - Allegations include that Inovio lacked sufficient information to justify the eligibility of the INO-3107 BLA for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [2]. - The public statements made by Inovio were claimed to be materially false and misleading throughout the relevant period [2]. Group 3: Investor Information - Investors who acquired shares of Inovio are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on April 7, 2026 [3].